annual meeting 2015 · welcome to the 2015 pcma annual meeting the pcma annual meeting is the...

CONFERENCE PROGRAMP A R T N E R S

P R E S I D E N T I A L S P O N S O R S

P C M A M E M B E R C O M P A N I E S

September 21 & 22 THE BROADMOOR COLORADO SPRINGS, CO

ANNUAL MEETING 2015

PCMA WOULD LIKE TO THANK THE FOLLOWING COMPANIES FOR THEIR SUPPORT OF THE 2015 ANNUAL MEETING

PARTNERS

PRESIDENTIAL SPONSORS

EXECUTIVE SPONSORS

GENERAL SPONSORS

ANNUAL MEETING | SEPTEMBER 21 & 22

Contents

Meeting Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Private Meeting Room Assignments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Broadmoor Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

Session Details & Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Member Company Lunch Receptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

PCMA Board of Directors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

PCMA Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

PCMA Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38

PCMA Affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39

Welcome to the 2015 PCMA Annual Meeting

The PCMA Annual Meeting is the industry’s premier executive conference. The event is tailored specifically for senior executives from PBMs and their affiliated business partners — most notably drug manufacturers. We’ve designed the Annual Meeting to be an important part of your business strategy and are proud of the unique value that the conference offers to PBM, specialty pharmacy and pharma industry executives.

The decision makers in attendance, educational insights, and business opportunities are ultimately what make the Annual Meeting so valuable. There are many pressing issues impacting the health care industry today, key among them are innovation and affordability. These and many other issues will be addressed both on and off the stage during the next two days. The interaction and dialogue that takes place at this event serves to promote continued industry collaboration addressing the many challenges we face.

We thank you for coming to this year’s Annual Meeting. We hope that you find your time spent to be enlightening and beneficial to your business. Enjoy your time at The Broadmoor.

Innovating Healthcare From Novel Medicines to Collaborative Relationships

Introducing Astellas Health Systems

Astellas Health Systems is dedicated to delivering innovative products to and forming lasting relationships with our customers. Our support programs are designed to help customers achieve their objectives as we continue to focus on key therapeutic areas that impact their members:

I Urology I Oncology I Transplantation I Cardiology I Anti-infectives

We’ve changed our look, but not our approach to providing customer-driven quality programs. We are Astellas Health Systems: Improving Healthcare Together.

©2015 Astellas Pharma US, Inc. All rights reserved. 080-0254-PM 4/15 Printed in USA.

ME

ETin

g in

fo

rM

ATio

nANNUAL MEETING | SEPTEMBER 21 & 22

Meeting information

RegistrationAll conference attendees are required to check in at the PCMA registration Desk.

Sunday, September 20 4:00 pm – 7:00 pm Broadmoor Main, Mezzanine Lobby

Monday, September 21 7:00 am – 9:00 am Broadmoor Main, Mezzanine Lobby

9:00 am – 12:00 pm International Center

12:00 pm – 6:00 pm Broadmoor Main Mezzanine Lobby

Tuesday, September 22 7:00 am – 9:00 am Broadmoor Main, Mezzanine Lobby

9:00 am – 12:00 pm International Center

12:00 pm – 5:00 pm Broadmoor Main, Mezzanine Lobby

name badges and conference materials will be available for pick-up during these hours. Photo identification must be provided in order to collect your materials.

green badges indicate drug manufacturers. Yellow badges indicate PBM, payer, specialty pharmacy and other industries.

if you require a copy of your registration confirmation, receipt of payment or invoice, please email Jenny Dawson at [email protected].

Conference FunctionsConference participants MUST wear badges when attending any conference sessions, meals, evening receptions, and private meetings in member and sponsor meeting room facilities. Event security will be monitoring entrances to all conference functions. Please do not misplace or forget badges, as duplicates will not be provided.

Shuttle TransportationShuttle service is provided to and from Cheyenne Mountain resort on Monday and Tuesday every 15 minutes beginning on the hour at 6:00 am and ending at 10:00 pm from the following locations:

The Broadmoor – Broadmoor Main Cheyenne Mountain resort – Front Drive

AttireAttire for all conference activities is business casual. Some evening receptions will be held outdoors. Please be prepared for cooler temperatures.

InternetWi-fi is not available in international Center or in private meeting rooms, but can be accessed while in the lobby and other public spaces.

Presentations Presentations authorized for distribution will be posted online. Attendees will be notified by email once presentations are available.

PhotographyProfessional photographs taken during the conference may be posted online and printed in future materials.

Mobile/Smartphone PolicyAs a courtesy to presenters and fellow attendees, phones should be turned to silent during all conference functions. Please minimize use during conference sessions.

DisclaimerThe opinions expressed by program participants are those of the individual presenters. They do not necessarily reflect the views of PCMA or its members.

Attendance at a Pharmaceutical Care Management Association (PCMA) meeting or event includes the limited, non-exclusive, revocable, and non-transferable right and license to use any PCMA materials, whether written, oral or electronic, made available by PCMA to the attendees for informational or personal use purposes only. PCMA reserves all other rights. PCMA or its licensors own all rights in and to all of its presentations, content, designs, methodologies, processes, programs, products, information, and documentation. PHArMACEUTiCAL CArE MAnAgEMEnT ASSoCiATion, PCMA and all other names, logos and icons identifying PCMA and its products and services are proprietary trademarks of PCMA, and any use of such marks without the express written permission of PCMA is strictly prohibited.

Pr

ivA

TE

ME

ETin

g r

oo

M A

SS

ign

ME

nTS

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Private Meeting room AssignmentsPlease find all private meeting room assignments listed below. To help you locate these rooms, we have provided a resort map of The Broadmoor on the following page. Please note that anyone entering meeting rooms must be registered for the conference and wearing a badge.

Contact Jenny Dawson, jdawson@pcmanet .org, or check in at the PCMA Registration Desk with any questions related to private meeting space .

Partner & Presidential Sponsors Meeting Room Room Location within Resort (see map)

Abbvie northeastmoor, 1st floor, room 2710 northeastmoorAllergan northeastmoor, 2nd floor, room 2809 northeastmoorAmgen northeastmoor, 1st floor, room 2711 northeastmoorAstellas russell Boardroom Broadmoor SouthAstraZeneca northeastmoor, 1st floor, room 2706 northeastmoorBaxalta northeastmoor, 2nd floor, room 2811 northeastmoorBayer northeastmoor, 1st floor, room 2704 northeastmoorBiogen Schreyvogel Boardroom Broadmoor SouthBoehringer ingelheim northeastmoor, 1st floor, room 2712 northeastmoorCelgene farney Boardroom Broadmoor SouthCoverMyMeds northeastmoor, 2nd floor, room 2801 northeastmoorEMD Serono, inc. northeastmoor, 1st floor, room 2709 northeastmoorgenentech northeastmoor, 1st floor, room 2703 northeastmoorgilead northeastmoor, 1st floor, room 2715 northeastmoorglaxoSmithKline northeastmoor, 2nd floor, room 2805 northeastmoorLilly USA, LLC northeastmoor, 1st floor, room 2707 northeastmoornovartis northeastmoor, 2nd floor, room 2815 northeastmoornovo nordisk northeastmoor, 1st floor, room 2701 northeastmoorPfizer northeastmoor, 2nd floor, room 2803 northeastmoorSanofi northeastmoor, 2nd floor, room 2807 northeastmoorSunovion Pharmaceuticals northeastmoor, 2nd floor, room 2806 northeastmoorTakeda northeastmoor, 2nd floor, room 2804 northeastmoorTeva remington Boardroom Broadmoor South

Executive & General Sponsors PCMA Members

Acorda Aetna

Companies to the left have access to shared rooms for private meetings. The rooms are located in northeastmoor and Broadmoor West. Please reference the following page for exact locations.

Be sure to confirm the name of your meeting room with the meeting organizer.

Please begin and end meetings in shared rooms on time . Another meeting might immediately precede or follow yours .

Actelion Pharmaceuticals CignaAvanir CvS HealthBristol-Myers Squibb Express ScriptsDaiichi Sankyo, inc. Humana Pharmacy Solutions Eisai LDi integrated Pharmacy ServicesEndo Medimpactgrifols optumrxHospira Prime Therapeutics indivior US Script Johnson & JohnsonLundbeckMallinckrodt Pharmaceuticals MedivationMerck MylanotsukaPurdue PharmaShireUCBUpsher-Smith Laboratoriesvaleantvertex

Br

oA

DM

oo

r M

AP


Broadmoor Map

NO

RT

HEA

STM

OO

RM

EET

ING

RO

OM

SR

OO

M N

UM

BER

S

2701

–281

5

MA

IN P

OO

LC

OM

PLE

X

CO

NFE

RE

NC

E A

CTI

VITI

ES

FOU

NTA

IN R

OO

M

© 2015 Biogen. All rights reserved. 07/15 FCH-US-0947

Caring deeply about those around usWe know that living with multiple sclerosis (MS) can present some pretty

large challenges. At Biogen™, we are committed to patients through

ongoing research and support services to help meet unmet needs in

the management of MS.

Visit Biogen.com, or call 1 800 456 2255.

SC

HE

DU

LE

-AT-A

-gLA

nC

EANNUAL MEETING | SEPTEMBER 21 & 22

Schedule-at-a-glance

Monday, September 21

7:00 am – 6:00 pm Registration Hours & Locations

7:00 am – 9:00 am: Broadmoor Main, Mezzanine Lobby 9:00 am – 12:00 pm: International Center12:00 pm – 6:00 pm: Broadmoor Main, Mezzanine Lobby

7:00 am – 6:00 pm Private Meeting Rooms Open

Please reference page 4 for room assignments and locations.

8:00 am – 9:30 am Networking Breakfast Broadmoor Main, Lake Terrace Dining Room

9:30 am – 12:30 pm CONFERENCE SESSIONS

Conference Moderator: Susan Dentzer, Senior Policy Advisor robert Wood Johnson foundation

International Center

9:30 am – 10:00 am Partnership in Medical Innovation: Delivering Value for Patients, Health Care Systems and the Economy

Bob Hugin, Chairman & Chief Executive Officer, Celgene


10:00 am – 10:45 am Trade Relations Panel

Ed Adamcik, Vice President, Pharma Strategy and Contracting Express Scripts

Pete Clagett, Senior Vice President, Cost of Care and Specialty Prime Therapeutics

Moderator: Kenton Stewart, Executive Vice President, Health Systems, Astellas Pharma US, inc.


10:45 am – 11:15 pm Analysis of the 340B Drug Program Omnibus Guidance

Kevin Host, President, PSg Consulting


11:15 am – 12:00 pm A Wall Street Perspective on Market Evolution and Consolidation Trends

robert Willoughby, Managing Director & Senior Equity Research Analyst, Bank of America Merrill Lynch

Peter Costa, Managing Director & Senior Equity Research Analyst Wells fargo Securities, LLC

Moderator: Susan Dentzer, Senior Policy Advisor robert Wood Johnson foundation


SC

HE

DU

LE

-AT-A

-gLA

nC

EPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

12:30 pm – 2:00 pm Member Company Receptions and Networking Lunch

» Cigna – Crystal Room

» CVS Health – Main Ballroom

» Humana Pharmacy Solutions – Pompeiian Room

» Prime Therapeutics – Lake Terrace Dining Room

Networking Lunch – Fountain Room

Broadmoor Main

2:00 pm – 6:30 pm Private Meetings and Networking Break

if you’re not in a private meeting, be sure to spend some time in the main lobby to catch up with old colleagues and make new business connections. We’ll have designated space for just this purpose, as well as refreshments throughout the afternoon.

Broadmoor Main, Mezzanine Lobby

6:30 pm – 10:00 pm Cocktail and Dinner Reception with Live Music

Transportation will begin at 6:15 pm from Broadmoor South and Broadmoor West and will continue to make loops every 15 minutes throughout the evening.

Cheyenne Lodge

Tuesday, March 17

7:00 am – 5:00 pm Registration Hours & Locations

7:00 am – 9:00 am: Broadmoor Main, Mezzanine Lobby 9:00 am – 12:00 pm: International Center12:00 pm – 5:00 pm: Broadmoor Main, Mezzanine Lobby

7:00 am – 8:00 pm Private Meeting Rooms Open

Please reference page 4 for room assignments and locations.

8:00 am – 9:00 am Networking Breakfast Broadmoor Main, Lake Terrace Dining Room

9:00 am – 12:30 pm CONFERENCE SESSIONS International Center

9:00 am – 9:45 am Opening Remarks

Mark Merritt, President & Chief Executive Officer, PCMA

Industry Leadership Panel Discussion Sustainable Health Care: Promoting Innovation Alongside Affordability

Jon roberts, President, CvS/caremark & Executive Vice President CvS Health

Dave ricks, Senior Vice President & President, Lilly Bio-Medicines, Eli Lilly and Company

Jim robinson, President, Astellas Pharma US, inc.

Mark Thierer, Chief Executive Officer, optumrx

Moderator: Steve Miller, Senior Vice President & Chief Medical Officer, Express Scripts


SC

HE

DU

LE

-AT-A

-gLA

nC

EANNUAL MEETING | SEPTEMBER 21 & 22

9:45 am – 10:20 am An Economist’s Observations of the US Health Care System

Amitabh Chandra, Malcolm Weiner Professor of Public Policy & Director of Health Policy Research, Harvard Kennedy School of government


10:20 am – 11:00 am Beyond Competitive Unit Cost: Advancing Outcomes Incentive Alignment

Chris Bradbury, Senior Vice President, Integrated Clinical Solutions and Specialty Pharmacy, Cigna Pharmacy Management

Thomas Stambaugh, Vice President, Cigna Specialty Pharmacy

Moderator: Kent rogers, Principal Consultant, Blue fin group


11:00 am – 11:35 am Biosimilars Market Analysis: Hurdles and Opportunities

ronny gal, Senior Analyst, Global Specialty Pharmaceuticals Sanford Bernstein


11:35 am – 12:10 pm Bending the Trend Through Personalized Pharmacy Interventions

Andrea Marks, Vice President & Chief Analytics Officer, optumrx


12:30 pm – 2:00 pm Member Company Receptions and Networking Lunch

» Aetna – Lake Terrance Dining Room

» Express Scripts – Main Ballroom

» OptumRx – Pompeiian Room

Networking Lunch – Fountain Room

Broadmoor Main

2:00 pm – 8:00 pm Private Meetings and Networking Break

if you’re not in a private meeting, be sure to spend some time in the main lobby to catch up with old colleagues and make new business connections. We’ll have designated space for just this purpose, as well as refreshments throughout the afternoon.

Broadmoor Main, Mezzanine Lobby

8:00 pm – 10:00 pm Cocktail and Dessert Reception Broadmoor Main, Lobby Bar

Patients, Science, and Innovation are the foundation of everything we do. At Celgene, we believe in an unwavering commitment to medical innovation, from discovery to development. Our passion is relentless—and we are just getting started.

© 2015 Celgene Corporation 07/15 US-CELG150237a

Session Details & Notes

SE

SS

ion

DE

TA

iLS

& n

oTE

SANNUAL MEETING | SEPTEMBER 21 & 22

Session Details & notes

Monday, September 219:30 am – 10:00 am International Center

Partnership in Medical Innovation: Delivering Value for Patients, Health Care Systems and the Economy

Bob Hugin, Chairman & Chief Executive Officer, Celgene

A strong health care system requires a collaborative ecosystem including health plans, pharmacy benefit managers, government agencies, academic institutions, healthcare providers, biopharmaceutical and medical innovators, and patient advocates. Successful partnership among all these sectors will produce value in medical innovation that helps patients live longer and better lives, reduces the burden on healthcare systems and grows our economy.

SE

SS

ion

DE

TA

iLS

& n

oTE

SPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Monday, September 2110:00 am – 10:45 am International Center

Trade Relations Panel

Ed Adamcik, Vice President, Pharma Strategy and Contracting, Express Scripts

Pete Clagett, Senior Vice President, Cost of Care and Specialty, Prime Therapeutics

Moderator: Kenton Stewart, Executive Vice President, Health Systems, Astellas Pharma US, inc.

This session explores key issues that PBM pharma relations and pharma market access executives are facing in the age of specialty. The topics addressed during this discussion are meant to provide the audience with a glimpse into the current and emerging challenges and opportunities that PBMs and pharma are facing in their day to day business interactions.

Topics that will be addressed during the discussion include:

» innovation, affordability, and value;

» PBM management strategies for the rising cost and affordability of drugs;

» Considerations around risk;

» opportunities for minimizing fraud, waste and abuse; and

» Manufacturer Collaboration with PBMs.

SE

SS

ion

DE

TA

iLS

& n

oTE


Monday, September 2110:45 am – 11:15 pm International Center

Analysis of the 340B Drug Program Omnibus Guidance

Kevin Host, President, PSg Consulting

340B Drug Pricing Program omnibus guidance was released in late August and proposes guidance for covered entities enrolled in the 340B Program and drug manufacturers that are required by section 340B of the PHSA to make their drugs available to covered entities under the 340B Program. After consideration of public comments, the final guidance will be intended to assist 340B covered entities and drug manufacturers in complying with the statute.

During this session, Kevin Host will provide the audience with an analysis is of the guidance. He will discuss the genesis of the program and why it has been ambiguous, the difference in purchasing points between covered entities and non-covered entities, new compliance requirements, how the scope of the program impacts the big picture of US drug spend, and why manufacturers and PBMs are playing, or not playing, in the space.

SE

SS

ion

DE

TA

iLS

& n

oTE


Monday, September 2111:15 am – 12:00 pmInternational Center

A Wall Street Perspective on Market Evolution and Consolidation Trends

robert Willoughby, Managing Director & Senior Equity Research Analyst, Bank of America Merrill Lynch

Peter Costa, Managing Director & Senior Equity Research Analyst, Wells fargo Securities, LLC

Moderator: Susan Dentzer, Senior Policy Advisor, robert Wood Johnson foundation

Wall Street analysts always offer a highly informed perspective of our industries. During this fireside chat-style session, Bob Willoughby and Peter Costa will provide their perspectives on various trends related to drug channel evolution including:

» The ACA, channel consolidation, and scale;

» Pharma innovation and reimbursement pressure;

» The future role of drug retail;

» opportunity in managing specialty and predictions for PCSK9s;

» Biosimilars; and

» Tightening payer and PBM controls.

SE

SS

ion

DE

TA

iLS

& n

oTE


Tuesday, September 229:00 am – 9:45 am


Opening Remarks

Mark Merritt, President & Chief Executive Officer, PCMA

Industry Leadership Panel Discussion Sustainable Health Care: Promoting Innovation Alongside Affordability

Jon roberts, President, CvS/caremark & Executive Vice President, CvS Health

Dave ricks, Senior Vice President & President, Lilly Bio-Medicines, Eli Lilly and Company

Jim robinson, President, Astellas Pharma US, inc.

Mark Thierer, Chief Executive Officer, optumrx

Moderator: Steve Miller, Senior Vice President & Chief Medical Officer, Express Scripts

Discussions around a sustainable health care model are becoming more and more prevalent amongst industry insiders, economists, policy makers, and consumers alike. This panel brings together leaders from the pharmaceutical manufacturer and PBM industries to discuss their shared interests in brining innovative products to market that address unmet medical needs in the most effective and affordable way for the system.

During this session, the panel will discuss industry strategies, market trends, and collaboration opportunities. Discussion topics will include:

» The importance of data and its role in defining value;

» Biosimilars and their role in an open and competitive marketplace;

» international pricing models, international drug approvals, and international patient data; and

» 21st Century Cures and other industry regulatory challenges and opportunities.

SE

SS

ion

DE

TA

iLS

& n

oTE


Tuesday, September 229:45 am – 10:20 amInternational Center

An Economist’s Observations of the US Health Care System

Amitabh Chandra, Professor of Public Policy & Director of Health Policy Research, Harvard Kennedy School of government

Public policy plays an ever-increasing role in our health care market. The US government’s role as both health care payer and regulator complicates the market. With health care cost and coverage challenges increasing at the same time that pharmaceutical innovation is at its greatest point in years, we need to understand how public policy impacts marketplace dynamics and progress.

During this session, Profession Chandra will share some of his observations around:

» Predictions for further, post-ACA policy, regulatory, and marketplace changes;

» Challenges federal and state governments face when budgeting for health care spend;

» Payer coverage decisions and pricing strategies — predictions about bundled payments, reference pricing, licensing, etc.;

» ACos and their future role in this complicated system;

» The long term role of exchanges and their market share;

» Biosimilars impact on drug pricing;

» Consumer choice — people with different income levels being willing to spend different amounts of money for different coverage quality; and

» How the audience might think about their organizations’ role in the debate.

SE

SS

ion

DE

TA

iLS

& n

oTE


Tuesday, September 2210:20 am – 11:00 pm International Center

Beyond Competitive Unit Cost: Advancing Outcomes Incentive Alignment

Chris Bradbury, Senior Vice President, Integrated Clinical Solutions and Specialty Pharmacy, Cigna Pharmacy Management

Thomas Stambaugh, Vice President, Cigna Specialty Pharmacy

Moderator: Kent rogers, Principal Consultant, Blue fin group

industry players and plan sponsors continue to focus heavily on improving drug therapy “unit cost” and utilization management as primary drivers of affordability. With new drug entrants, more therapeutic alternatives and rising drug prices, the need and opportunity to expand outcomes incentive alignment with manufacturers and healthcare providers are growingly rapidly. This session highlights the progression of outcomes incentive alignment, criteria for consideration, and plan sponsor expectations.

SE

SS

ion

DE

TA

iLS

& n

oTE


Tuesday, September 2211:00 am – 11:35 pm International Center

Biosimilars Market Analysis: Hurdles and Opportunities

ronny gal, Senior Analyst, Global Specialty Pharmaceuticals, Sanford Bernstein

Biosimilars are here. Sandoz’s first biosimilar in the US launched the first week in September, finally making biosimilars a reality to US market. During this session ronny gal will discuss how these products will start to penetrate the US market. He will address the evolution of biosimilars and the pipeline of products, lessons we can learn from Europe, the current legal and iP landscape, approval and regulatory issues, financial models around revenues, profitability and margins, and strategies payers are considering for these new products.

SE

SS

ion

DE

TA

iLS

& n

oTE


Tuesday, September 2211:35 am – 12:10 pmInternational Center

Bending the Trend Through Personalized Pharmacy Interventions

Andrea Marks, Vice President & Chief Analytics Officer, optumrx

CMS has been pushing payers for reviews of cost savings opportunities and improvements in adherence in the Medicare population. During this session, Andrea Marks will present outcomes from a first-of-its-kind randomized control trial of a medication therapy management (MTM) and retrospective drug utilization review (rDUr) intervention in a large commercial patient population. Data from this trial demonstrates that savings are directly attributable to drug adherence programs with wrap around counseling and MTM programs. This was shown to be particularly true in this trial for diabetes and CoPD/asthma patients, showing the value of pharmaceutical care and the opportunity it provides for savings.

SE

SS

ion

DE

TA

iLS

& n

oTE


quick, which wordjumps out at you?

© 2012 Novo Nordisk Printed in the U.S.A. 0712-00010440 -1 October 2012

For nearly a century, we have been committed to ending diabetes. And as a leader in research, education, and unique partnerships, we’re nearly there. Because we never lose sight of the fact that every day patients like Katie dream about a future free from their disease. And that’s why we believe that together we can defeat diabetes in our lifetime. For more about us, visit novonordisk-us.com.

KATIE NORTONKatie has type 1 diabetes

CHANGESSUPPORT

FAMILYTOGETHER

ME

MB

Er

Co

MP

An

Y L

Un

CH

rE

CE

PTio

nS


Member Company Lunch receptionsMonday and Tuesday, September 21 and 22 12:30 pm – 2:00 pmSelect PCMA members host receptions exclusively for conference attendees from the drug manufacturer industry (designated by a blue badge). These Member Company receptions bring together all attendees from each PBM host company and offer excellent opportunities for networking and one-on-one interactions between PBM, specialty pharmacy, and pharma executives.

This year’s Member Company Receptions will take place concurrently during lunch, from 12:30 pm until 2:00 pm, on Monday and Tuesday . Each participating company will host a reception on one of the two days .

Lunch will be served in various reception rooms. Manufacturer attendees will be able to flow in and out of the individual receptions while individuals with companies not hosting or attending one of the receptions are welcome to eat and network in The Fountain Room. Please note that in addition to manufacturers wearing green badges, only employees of the host company are permitted in their respective reception rooms.

MONDAYCigna – Crystal Room

CvS Health – Main Ballroom

Humana Pharmacy Solutions – Pompeiian Room

Prime Therapeutics – Lake Terrace Dining Room

open networking Lunch – Fountain Room

TUESDAYAetna – Lake Terrance Dining Room

Express Scripts – Main Ballroom

optumrx – Pompeiian Room

open networking Lunch – Fountain Room

ELEVATOR

RESTROOMS

ES

CA

LATO

R

POMPEIIAN ROOM

MEZZANINE LOBBY

CENTER LOUNGE

MAINBALLROOM

MAINBAR

FOUNTAINROOM

CRYSTALROOM

LAKE TERRACEDINING ROOM

BROADMOOR MAIN MEZZANINE LEVEL

Teva Pharmaceuticals is working every day to make

quality healthcare accessible around the world.

As a manufacturer of specialty and generic

pharmaceuticals, Teva provides both new therapies

and greater access to quality, affordable medicines.

tevausa.com

We Make Quality Healthcare Accessible

SP

EA

KE

rS


Speakers

Ed AdamcikVice President, Pharma Strategy and ContractingExpress Scripts

Ed Adamcik is vice President of Pharma Strategy and Contracting at Express Scripts (ESi). in his current role, Adamcik is responsible for all rebate contracting and strategy at ESi (commercial, Med-D, Medicaid, exchange, specialty, and medical). in addition, his team is responsible for formulary consulting for all of ESi’s health plan clients. His dedicated teams meet with accounts to review strategies and opportunities to maximize the value of their formulary.

Prior to the ESi/Medco merger, Adamcik was vice President of Pharma Strategies and Solutions at Medco Health. His principle responsibility was managing brand pharma relationships for both commercial and part D books of business. He was responsible for roughly half of Medco’s pharma relationships. in addition, he was responsible for consulting with key health plans to maximize the value of their formulary content and plan design. His group was responsible for United Health group, Coventry Health Plan, and all clients that follow Medco’s Preferred Prescriptions formulary. Adamcik joined Medco in an operations role as a Pharmacy Manager responsible for managing 150 pharmacists in the nJ mail facility. He then moved on to the Marketing department where he was responsible for the development of a physician report card.

Adamcik practiced retail pharmacy for three years. Prior to joining Medco, he served as Director of formulary Management with national Prescription Administrators.

Adamcik is a graduate of rutgers University College of Pharmacy and also earned his master’s degree from rutgers University. Adamcik is an active member of rutgers College of Pharmacy Alumni Association.

Adamcik is married with one child. outside work, he is very involved with youth baseball and is an avid golfer and rutgers supporter.

Christopher BradburySenior Vice President, Integrated Clinical Solutions and Specialty PharmacyCigna Pharmacy Management

Chris Bradbury is currently the integrated Clinical Solutions and Specialty Pharmacy Leader within Cigna Pharmacy Management. in addition to driving Cigna’s pharmacy clinical strategies and specialty pharmacy business, he leads Cigna Pharmacy’s efforts to integrate pharmacy capabilities and customer touchpoints to support Cigna’s overall strategy to engage customers faster and deeper to improve health and lower total health care costs.

Prior to joining Cigna in 2013, Bradbury spent fifteen years at Medco Health Solutions where he led many of the PBM’s Clinical and integrated Data Patient Safety Solutions as well as the Population Health, Chronic Care Management and Care Coordination solutions. in addition, he served as a management consultant for six years, focused on business strategy, process reengineering, strategic sourcing, and benchmarking in the health care and financial services industries.

Bradbury earned his Bachelor of Business Administration in finance from georgetown University and earned his Master of Business Administration from MiT’s Sloan School of Management.

SP

EA

KE

rS


Amitabh ChandraMalcolm Weiner Professor of Public Policy & Director of Health Policy ResearchHarvard Kennedy School of Government

Amitabh Chandra is the Malcolm Weiner Professor of Public Policy and Director of Health Policy research at the Harvard Kennedy School of government. He is a member of the Congressional Budget office’s Panel of Health Advisors, and he is a research Associate at the iZA institute in Bonn, germany and at the national Bureau of Economic research. At Harvard, Professor Chandra teaches undergraduates in Harvard College, graduate students at the Kennedy School and Business School, and in Harvard’s Executive Education programs.

His research focuses on innovation and cost-growth in health care, medical malpractice, and racial disparities in health care. His research has been supported by the national institute of Aging, the national institute of Child Health and Development, the robert Wood Johnson foundation, and has been published in the American Economic Review, the Journal of Political Economy, the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is an editor of the Review of Economics and Statistics, a former editor of the Journal of Human Resources, and serves on the editorial boards of Economics Letters and the American Economic Journal.

Chandra has testified to the United States Senate and the United States Commission on Civil rights. His research has been featured in The New York Times, The Washington Post, Cnn, Newsweek, and on national Public radio. He has been a consultant to the rAnD Corporation, Microsoft research, the institute of Medicine, and the Blue Cross Blue Shield foundation of Massachusetts. in 2011 he served as Massachusetts’ Special Commissioner on Provider Price reform. Professor Chandra is an elected member of the institute of Medicine, the first-prize recipient of the Upjohn institute’s Dissertation Award, the Kenneth Arrow Award for best paper in health economics, and the Eugene garfield Award for the impact of medical research. in 2012, he was awarded the American Society of Health Economists (ASHE) Medal. The ASHE Medal is awarded biennially to the economist age 40 or under who has made the most significant contributions to the field of health economics.

Pete ClagettSenior Vice President, Cost of Care and SpecialtyPrime Therapeutics

As Prime Therapeutics’ Senior vice President of Cost of Care and Specialty, Pete Clagett has accountability for managing nearly $20 billion in annual prescription drug spend across all segments of Prime’s commercial and government business.

With the integration of medical and pharmacy care at the center of Prime’s value proposition, Clagett focuses Prime’s cost of care efforts beyond traditional pharmacy benefit

management to address key areas of clinical quality. This includes drug adherence in high-risk populations, gaps in care, as well as the care of patients requiring complex specialty medications to deliver better total health outcomes for the people Prime serves.

Clagett manages Prime’s Clinical, Health outcomes, Specialty, Trade relations, Pharmacy networks, Audits, and Enterprise reporting and Analytics Teams.

Clagett is a respected leader with more than 25 years of industry experience. He has deep knowledge and experience in regulated markets and delivering financial value to clients. Previously, Clagett served as President and Chief Executive officer of US Script. He has also held senior leadership positions at Anthem and glaxoSmithKline.

Clagett received his Bachelor of Arts degree from the University of California, Santa Cruz and an executive Master of Business Administration from golden gate University. Clagett also currently serves on the Board of Advisors for Keck graduate institute School of Pharmacy.

SP

EA

KE

rS


Peter CostaManaging Director & Senior Equity Research AnalystWells Fargo Securities, LLC

Peter Costa is a Managing Director at Wells fargo Securities covering the Managed Care and Pharmacy/Ancillary Benefits sectors. in addition to his current sectors, he has also covered a broad spectrum of other health care service or medical-focused sectors for several firms over the past 25 years. He has been ranked by The Wall Street Journal as a top stock picker in multiple categories.

Previously, he was a Senior research Analyst and the Director of Equity research at fTn Equity Capital Markets and Leerink Swann, and a Senior research Analyst and the Head of global Health Care and Pharmaceutical research at ABn AMro. He has also worked at other firms, including Morgan Stanley, Arthur Andersen, and Hewlett-Packard’s medical imaging business.

Costa earned a Bachelor of Science in industrial and Management Engineering from rensselaer Polytechnic institute and an MBA from Dartmouth’s Tuck School of Business.

Susan DentzerSenior Policy AdvisorRobert Wood Johnson Foundation

Susan Dentzer is Senior Policy Adviser at the robert Wood Johnson foundation, the nation’s largest health and health care philanthropy, based in Princeton, new Jersey. in this role, she works closely with foundation leaders to carry out the organizational mission of improving the health and health care of all Americans. one of the nation’s most respected health and health policy thought leaders and journalists, Dentzer is also an on-air analyst on health issues on the PBS NewsHour.

Dentzer is an elected member of the institute of Medicine and the Council on foreign relations. She is also a fellow of both the national Academy of Social insurance and the Hastings Center, and she is a public trustee of the American Board of Medical Specialties. Dentzer is also a member of the board of directors of research!America, which advocates for increased US investment in biomedical research.

Dentzer is a frequent guest and commentator on such national Public radio shows as This American Life and The Diane Rehm Show. from May 2008 to April 2013, Dentzer was the Editor-in-Chief of Health Affairs, the nation’s leading journal of health policy, where she transformed the journal from a bimonthly academic publication to a highly readable and topical monthly journal and on-line publication with more than 120 million page views annually.

Prior to joining the journal, Dentzer was an on-air correspondent on health and health policy for the PBS NewsHour with Jim Leher, where she earned numerous awards for her work. (The unit was supported by a grant from the robert Wood Johnson foundation.) Before joining NewsHour, Dentzer served as Chief Economics Correspondent and Economics Columnist for US News & World Report, and she was a Senior Writer for Newsweek.

A graduate of Dartmouth and holder of an honorary Master of Arts from the institution, Dentzer is a Dartmouth trustee emerita, and was the only woman to date to chair the Dartmouth Board of Trustees, which she did from 2001 to 2004. Winner of the Dartmouth Alumni Award, the Young Alumni Award, and the Dartmouth Presidential Medal for Achievement, she has served on the Board of overseers of Dartmouth Medical School since 1993.

Dentzer, her husband, and their three children live in the Washington, DC area.

SP

EA

KE

rS


Ronny GalSenior Analyst, Global Specialty PharmaceuticalsSanford Bernstein

Aaron (ronny) gal is the Senior Analyst at Sanford Bernstein covering global Specialty Pharmaceuticals. gal provides research and investment insight on specialty pharmaceutical stocks to institutional clients around the world.

Prior to joining Bernstein in 2004, gal spearheaded Canon’s business development in life sciences. He also spent six years with the Boston Consulting group, advising clients in the pharmaceuticals and health care delivery industries.

gal was awarded a PhD from the Massachusetts institute of Technology and holds a Bachelor of Science from Emory University. gal has been named the no. 1 analyst in institutional investor’s All-America research Team survey for the past six years.

Kevin Host PresidentPSG Consulting

Kevin Host leads the PSg consulting group. With more than 20 years of experience in the pharmaceutical benefit industry, he has a strong background in specialty benefit management, product development, pharmacy operations, and mentoring emerging leaders.

Prior to joining PSg, Host served as Senior vice President of Specialty Pharmacy at optumrx and was responsible for UnitedHealth group’s optumrx Specialty Pharmacy

programs, which included specialty drug distribution, clinical program development, and benefits and outcomes strategy designs.

Host earned his Doctor of Pharmacy from the University of the Pacific in California. He also is a member of various industry boards, including the Genentech Oncology Trend Report and the UrAC Pharmacy Advisory group, where he helped establish the first comprehensive accreditation standards for specialty and mail service pharmacies.

Robert HuginChairman and Chief Executive OfficerCelgene

Bob Hugin serves as Chairman and Chief Executive officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of the company since December 2001.

Hugin is past Chairman of the Board of The Pharmaceutical research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, The Medicines Company, and The Darden foundation at the University of virginia. He also serves as a member of the Board of Trustees of Atlantic Health System and of family Promise, a national non-profit network assisting homeless families.

Prior to joining Celgene, Hugin was a Managing Director with J.P. Morgan & Co. inc. Hugin received an AB degree from Princeton University and an MBA from the University of virginia. He served as a United States Marine Corps infantry officer between 1976 and 1985. Bob and his wife, Kathy, have three children and live in Summit, new Jersey.

SP

EA

KE

rS


Andrea MarksVice President & Chief Analytics Officer OptumRx

Andrea Marks is vice President and Chief Analytics officer at optumrx, responsible for a full suite of analytics and outcomes, including clinical program analytics, formulary analytics, client insights, trend management, and innovative analytic product development. Before the recent Catamaran merger with optumrx, Marks served as Chief Analytics officer at Catamaran where she was responsible for leading comprehensive analytics, and outcomes development for the company’s full suite of clinical programs and innovative PBM services.

As a 20-year veteran specializing in health care, pharmacy, and managed care analytics, Marks is a seasoned leader who knows how to derive industry value from analytic insights. Marks joined Catamaran from Blue Health intelligence where she served as Chief informatics officer, responsible for analytic development of products and services, analytic consulting services, and management of the iT enablement services. Prior to Blue Health intelligence, Marks held progressive roles of responsibility at Blue Cross Blue Shield Association and CvS Caremark, always leading strategic analytics research and outcomes.

Marks holds a Bachelor of Science degree from Loyola University of Chicago and a Master of Science from DePaul University.

Mark MerrittPresident & Chief Executive OfficerPCMA

Mark Merritt is President and Chief Executive officer of PCMA, which represents the nation’s PBMs. The PBM industry plays a pivotal role in American health care, administering prescription drug benefits for over 200 million Americans covered by fortune 500 companies, health insurance plans, labor unions, and Medicare Part D.

Before joining PCMA, Merritt played senior roles with America’s Health insurance Plans, the Pharmaceutical research and Manufacturers of America, and the presidential campaigns of Senators Bob Dole and Lamar Alexander.

Merritt also served as a fellow at the Harvard Kennedy School of government, where he lectured on the intersection of politics, public policy, and the media. Merritt is known for innovative, campaign-style public relations strategies that reach beyond Washington to Wall Street, Main Street, even Hollywood.

in 2003, Merritt took the helm of PCMA and quickly bolstered its stature and clout. He is routinely ranked among the nation’s most effective association executives, and he is a member of the US Chamber of Commerce’s elite “Committee of 100.” recognizing his tireless efforts promoting affordable medicines, the generic Pharmaceutical Association selected Merritt for its 2011“outstanding Contribution” award.

Merritt serves on the Editorial Advisory Board for Drug Benefit News and the Board of The Public Affairs Council, which represents communications professionals worldwide.

He holds a BA and an MA from georgetown University. He and his wife, Jayne, have four children.

SP

EA

KE

rS


Steve MillerSenior Vice President & Chief Medical OfficerExpress Scripts

Dr. Steve Miller, a leading advocate for fair drug pricing, supports Express Scripts’ government relations, leads the Pharmacy & Therapeutics Committee, manages the Medical Affairs team and interfaces with client groups. His expertise represents years as a medical researcher, clinician, and administrator, and spans numerous healthcare subjects.

Miller has served as Chief Medical officer since 2006, focused on clinical matters including e-prescribing initiatives, specialty solutions, and overall development of products that make

prescription drugs safer and more affordable. He previously was the vice President and Chief Medical officer at Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis.

Miller received his medical degree from the University of Missouri-Kansas City. He trained in the Pathology and research fellowship at the University of Alabama at Birmingham. He was the William J. and Dorothy fish Kerr fellow in Cardiology at the University of California, San francisco. Miller also did internal Medicine training at the University of Colorado and nephrology and Transplantation at Washington University in St. Louis. He earned his MBA at the olin School of Business at Washington University.

Dave RicksSenior Vice President & President, Lilly Bio-Medicines Eli Lilly and Company

Dave ricks is Senior vice President of Eli Lilly and Company and President of Lilly Bio-Medicines. Lilly Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, urology, musculoskeletal, and autoimmunity, as well as the company’s global marketing and pricing, reimbursement, and access functions.

After joining Lilly in 1996 as a Business Development Associate, ricks held several management roles in US Marketing and Sales before moving to Lilly Canada, where he

served as Director of Pharmaceutical Marketing, as national Sales Director, and then as general Manager. He then was named President and general Manager of Lilly China before becoming President of Lilly USA in 2009.

Before joining Lilly, ricks worked for Hewlett-Packard and iBM.

ricks earned a bachelor’s degree in Business from Purdue University and a Master of Business Administration from indiana University.

ricks serves on the Board of governors for the riley Children’s foundation.

SP

EA

KE

rS


Jon RobertsPresident, CVS/caremark & Executive Vice PresidentCVS Health

Jon roberts is Executive vice President of CvS Health and President of CvS/caremark. in this role, roberts and his team are focused on reinventing pharmacy in order to help the company’s PBM clients improve health care outcomes for their members while managing overall health care costs. roberts also demonstrates a strong commitment to delivering excellent client service driven by a high level of quality, process development, and execution.

roberts has more than 30 years of pharmacy health care experience. He has developed a reputation as a results-driven leader, whose analytical approach has enabled him to successfully lead a diverse array of initiatives across the organization.

roberts previously served as Chief operating officer of the PBM business, supporting the company’s efforts to build a world-class infrastructure designed to address the changing needs of its PBM clients and their members. in that role, he was responsible for PBM and Specialty Pharmacy operations, Trade and Pharmaceutical Purchasing, Underwriting, and PBM networks. Prior to that role, he was Executive vice President of Pharmaceutical Purchasing, Pricing and network relations and also served as the company’s Chief information officer, where he spearheaded several key programs, including the Pharmacy Service initiative PSi, which significantly enhanced pharmacy performance at CvS/pharmacy, and was highlighted in business case studies at the Harvard Business School and Yale School of Management. He also served as Senior vice President of retail Store operations, following 20 years in retail field management positions.

roberts earned his degree in pharmacy from the virginia Commonwealth University School of Pharmacy. He is an active member of a number of Boards of Directors including PCMA; new Century Health, a specialty care management company; ALS Therapy Alliance, and he is a member of the ALS Association’s national Board of Trustees. roberts also is a member of the Advisory Council for the norman Prince neurosciences institute.

Jim RobinsonPresidentAstellas Pharma US, Inc.

Jim robinson is President of Astellas Pharma US, inc., a global research-based pharmaceutical company committed to serving unmet medical needs in oncology, immunology, infectious diseases, urology, neuroscience and DM complications, and kidney diseases. robinson leads the company’s commercial pharmaceutical operation in the US which spans across a diverse and growing portfolio in the oncology, urology, transplant, and cardiovascular markets. robinson has more than 20 years of experience in the pharmaceutical industry. He is a member of Astellas’ Management Committee.

Before assuming his present role, robinson was Senior vice President for Sales and Marketing and led the company’s expansion into the oncology area. robinson joined Astellas in 2005 as the vice President of Health Systems responsible for Managed Markets, reimbursement Strategy, State government Affairs, and government Accounts.

Prior to joining Astellas, he held increasingly more senior Marketing and Sales positions with Schering-Plough Pharmaceuticals in new Jersey. He started his career at Schering-Plough as a Sales representative and moved through positions of increasing responsibility until he was promoted to vice President of Hepatitis Sales and Managed Care. in this position he led the largest specialty pharmaceutical sales division within Schering-Plough.

robinson is a native of illinois and earned his Bachelor of Science and Marketing at DePaul University. He is a Board Member of the Pharmaceutical research & Manufacturers of America.

SP

EA

KE

rS


Kent RogersPrincipal ConsultantBlue Fin Group

Kent rogers is a recognized expert in product commercialization, payer strategy, and product development. With more than 20 years of experience in the pharmaceutical industry, he has worked for both large and small manufacturers. rogers has demonstrated a skill for critically assessing market issues, identifying key opportunities, and developing effective strategies to optimize business objectives.

rogers’ background and experience include primary care and specialty sales, contracting with private and public payers, hospitals and integrated health systems, federal markets, teaching institutions, product pricing, business development, health economics/outcomes research, channel strategy, and patient support services. He speaks frequently at industry events, and he is well-published on broad commercialization topics relating to pharmaceuticals.

Kenton Stewart Executive Vice President, Health SystemsAstellas Pharma US, Inc.

Kenton Stewart joined Astellas in 2006 and is Executive vice President of Health Systems. During his time at Astellas, he has also served as the Senior national Director of Contracts and Pricing.

Stewart’s past professional experience includes TAP Pharmaceuticals, where he served as Senior Director of Licensing and Business Development, Senior Director of national

Accounts, and Senior Manager of Business Development. Stewart also served as regional Sales Manager, Business Development Manager, and Electronic Drug Delivery Specialist at Abbott Laboratories, and as a Professional Medical representative at Syntex Laboratories.

Stewart has a bachelor’s degree in Marketing from Wichita State University and earned his master’s degree in Management from Bellevue University.

Mark ThiererChief Executive OfficerOptumRx

Mark Thierer was named Chief Executive officer of optumrx in 2015. in this role, he oversees all optum pharmacy care services, including the management of pharmacy benefits, pharmacy network, home delivery pharmacy, and specialty pharmacy programs.

Thierer previously served as Chairman of the Board and Chief Executive officer of Catamaran, one of the nation’s largest PBMs, which combined with optumrx in 2015.

During a 30-year career in health care, Thierer has built a track record of leading organizations to financial and operational success. He joined Catamaran in 2006 as President and Chief operating officer, and he was named President and Chief Executive officer in 2008.

Prior to Catamaran, Thierer led Physicians interactive, a division of Allscripts Healthcare Solutions, and he spent 10 years with Caremarkrx as a corporate officer and Senior vice President of industry relations. Prior to that, he held various sales management positions in the Health industry division of iBM.

Thierer earned a Bachelor of Science degree in finance from the University of Minnesota and a Master of Business Administration from nova Southeastern University. He is a frequent guest lecturer at business schools, including The Kellogg School of Management and Wharton, and he contributes as a board member to several organizations, including PCMA, the Lyric opera of Chicago, and CEos Against Cancer.

SP

EA

KE

rS


Robert WilloughbyManaging Director & Senior Equity Research AnalystBank of America Merrill Lynch

robert Willoughby is a Managing Director and Senior research Analyst in the Equity research department at Bank of America Merrill Lynch, where he covers 30 stocks in the Health Care Technology and Distribution sector with a focus on Pharmaceutical Services. He currently is the Health Care sector team leader.

Willoughby has been named to the “institutional investor All-America Team” for the past ten years. Prior to joining Bank of America Merrill Lynch, he was an Equity Analyst at Credit

Suisse first Boston, Dillon read, Merrill Lynch, and PaineWebber in new York. He started his career as an Equity research Associate at J.W. Charles Securities in Boca raton, florida.

Willoughby holds Bachelor of Arts degrees in Art History and Spanish from Bucknell University and a Master of Business Administration degree from the University of Michigan.

PC

MA

Bo

Ar

D o

f D

irE

CTo

rS


PCMA Board of Directors

Chairman, PCMA Board of DirectorsJon Roberts President, CVS/caremark & Executive Vice President CvS Health

Vice Chairman and Incoming Chairman, PCMA Board of DirectorsGeorge Paz Chairman & Chief Executive Officer Express Scripts

Jim DuCharme President & Chief Executive Officer Prime Therapeutics

Mark Thierer Chief Executive Officer optumrx

William Fleming President, Humana Pharmacy Solutions Humana inc.

Greg Watanabe President Medimpact Healthcare Systems, inc.

Chris Hocevar President, Select Segment & Cigna Pharmacy Management Cigna Corporation

Bill Wolfe Vice President, Pharmacy Aetna

PC

MA

STA

ff


PCMA Staff

Mark MerrittPresident & Chief Executive Officer

April AlexanderSenior Director, State Affairs

Kristin BassSenior Vice President, Policy and Federal Affairs

Tim BroganAssistant Vice President, Research and Policy

Megan CoderSenior Director, Industry Programs

Andy CosgroveVice President, Policy

Charles CotéVice President, Strategic Communications

Clem CypraAssistant Vice President, State Affairs

Jenny DawsonSenior Manager, Conferences and Development

Jonathan HeafitzSenior Director, Federal and Regulatory Affairs

Ryan HickeyDirector, Accounting and Operations

Greg JohnsonAssistant Vice President, Strategy

Jennifer JoslinExecutive Assistant to the President &

Chief Executive Officer

Wendy KrasnerVice President, Regulatory Affairs

Barbara LevyGeneral Counsel

Greg LopesSenior Director, Public Affairs

Jessica Mazer, Esq .Assistant Vice President, State Affairs

Brian McCarthyChief Operating Officer

Anne McCrawSenior Director, Industry Relations

Brenda PalmerChief Financial Officer

Kristen PumphreySenior Director, Conferences

Meagan RiordanDirector, State Affairs

Deloris TinsleyExecutive Assistant

Scott WoodsSenior Director, Policy

PC

MA

ME

MB

Er


PCMA Members

PC

MA

AffiL

iATE


PCMA Affiliates

OUR HEART IS ALWAYS IN OUR WORK BECAUSE OUR PATIENTS ARE ALWAYS ON OUR MIND.

AbbVie unites the spirit of a biotech with the strength of a successful pharmaceutical company to address the challenges patients face across the world. Our passion drives our science and expertise to develop and deliver new treatments that improve health and healthcare. Because every life is remarkable, our impact upon each must be equally so.

abbvie.com

We are a bold new healthcare company. We are one team of

dedicated employees, carving new paths, taking bold, decisive

actions to deliver results and better outcomes for patients

and providers.

We work in a fast-changing industry. We thrive in this environment.

We know that change = opportunity, and we are prepared to lead

change. We bring new ideas to render a powerful impact on human

lives around the world.

We love what we do. We have momentum. This is our moment.

We are the new Allergan.

www.Allergan.com

Meet the Bold new

Allergan

Working in Partnership with You

www.takeda.us Takeda Pharmaceuticals U.S.A., Inc. 89201

A new energy in the search for advanced pharmaceuticals.

Sunovion Pharmaceuticals Inc. is a leading pharmaceutical company dedicated to discovering, delivering and commercializing therapeutic products that advance the science of medicine and improve the lives of patients with central nervous system diseases and respiratory ailments.

Sunovion Pharmaceuticals Inc.

Visit us at www.sunovion.com

78479-R1-V1

SANOFI FOCUSED ON PATIENTS’ NEEDSOver the years, Sanofi has evolved to meet the new challenges of healthcare worldwide. Today, Sanofi is a global healthcare leader focused on patients. We listen to their needs, treat them, and provide support to them. Through our diversified portfolio of medicines, vaccines and innovative therapeutic solutions, we strive to protect the health and meet the needs of the world’s 7 billion people.

Sanofi is proud to support PCMA, the Pharmaceutical Care Management Association

More than18,000 employees in the United States

More than120 locations across North America

A comprehensive offering of medicines, vaccines and innovative services all over the world

© B

lue

Ima

ge

s/C

orb

is -

oo

yoo

/ge

tty im

ag

es

US.COR.14.06.005

For more information: www.sanofi.com – www.sanofi.us

www.facebook.com/sanofiUS www.twitter.com/sanofiUS www.pinterest.com/sanofiUS blog.sanofi.us

Hong Hu, Research Advisor, Lilly Research Laboratories

For 138 years, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/about.CA30092 05/14 PRINTED IN USA ©2015, Eli Lilly and Company. ALL RIGHTS RESERVED.

It begins with a promise to discover medicines that make life better.

Advancing Therapeutics,ImprovingLives.

For more information, please visit www.gilead.com.© 2015 Gilead Sciences, Inc.

For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.

What science can do

At AstraZeneca, we know improving the lives of patients requires engagement across all of healthcare, and we are committed to pursuing innovative collaborations that advance quality of care, improve patient outcomes and deliver value to the healthcare system.

We also work to support meaningful access to our medicines and actively engage patients in their own care along with their healthcare professionals to help slow progression of disease, reduce readmissions, and decrease complications.

To learn more about how AstraZeneca is pushing the boundaries of science to deliver life-changing medicines, transforming serious diseases like cancer, heart disease, diabetes, and asthma, visit astrazeneca-us.com.

© 2015 AstraZeneca. All rights reserved. 3133005 5/15

Advancing Quality of Patient Care

Oncology combination therapiesAstraZeneca is investigating combinationsof biologic and small-molecule therapies forthe treatment of cancer. These combinations target the tumor directly and some help boost the body’s own immune system to potentially induce cell death.

Your life. Our inspiration.

Baxalta Incorporated is a new global biopharmaceutical leader developing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Launched following the separation from Baxter International, Baxalta is driven by passion to make a meaningful impact for patients. At Baxalta, your life is our inspiration — that’s the promise of the Baxalta spark.

NYSE: BXLT | Baxalta.com

BXLT_Ad_FullPg_8x10.5.indd 1 7/28/15 10:09 AM

Passion to innovate | Power to change

At Bayer we encourage you to question the status quo and constantly think beyond the obvious. We foster open discussions, sharing knowledge across our community and partnering with external networks. We always start by

listening – because our customers are at the heart of everything we do. At Bayer you have the opportunity to be part of a culture where we value the passion of our employees to innovate and give them the power to change.

Boehringer Ingelheim ranks among the world’s 20 leading pharmaceutical corporations. Our vision drives us forward. It helps us to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition.

For more than 125 years, Boehringer Ingelheim has been committed to the research and development of innovative medicines that help make more health for patients and their families.

Nurturing innovative ideas todayfor more health tomorrow.

Farbe/colour:PANTONE 288 CV

Visit us online atus.boehringer-ingelheim.com

Elaine, patient

To us,science is personal.At Genentech, we’re passionate about fi nding solutions for people facing the world’s most diffi cult-to-treat conditions. That’s why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal.

Find out more at gene.com

128_Elaine_Actemra_7_5x10_4c_en.indd 1 29.01.15 09:57

The Largest Prior Authorization Network Integrated in the Clinical Workflow

360+INTEGRATED EHRs

72%OF U.S. PRESCRIPTION VOLUME

80%OF PHARMACY MARKET

400,000+ PRESCRIBERS45,000+ PHARMACIES

Learn more: covermymeds.com • 866.452.5017

Helping you manage complexity is our specialtyInnovative insights and focused expertise to help you improve outcomes and lower costs

Fertility • Endocrinology • Neurodegenerative Diseases • Oncology • Immuno-Oncology • Immunology

US-NON-1214-0007(1) © 2014 EMD Serono, Inc. EMD Serono, Inc. is a subsidiary of Merck KGaA, Darmstadt, Germany

• Industry-leading specialty pharmacy trend data to guide strategic decisions

• Customized approaches to support appropriate use, improve adherence, and minimize waste

• Partnerships designed to help you meet your quality goals

EMD Serono Managed Markets

ESMM14ENTR1141_A_EMDS_Convention_Ad_for_Oncology_r7.indd 1 5/15/15 3:42 PM

For patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

◆ Otezla was evaluated in 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients with moderate to severe plaque psoriasis (N = 1257) were randomized 2:1 to Otezla 30 mg or placebo twice daily for 16 weeks, after a 5-day titration1,2

◆ Inclusion criteria: Age ≥18 years, BSA involvement ≥10%, sPGA ≥3, PASI score ≥12, candidates for phototherapy or systemic therapy1

◆ PASI-75 response at week 16 (primary endpoint)1,2

– Study 1: Otezla 33% vs placebo 5% (P < 0.0001)– Similar PASI-75 response was achieved in Study 2

BSA, body surface area; PASI, Psoriasis Area and Severity Index; sPGA, static Physician Global Assessment.

IMPORTANT SAFETY INFORMATIONContraindications◆ Otezla® (apremilast) is contraindicated in patients with a

known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions◆ Depression: Treatment with Otezla is associated with an

increase in adverse reactions of depression. During clinical trials, 1.3% (12/920) of patients treated with Otezla reported depression compared to 0.4% (2/506) on placebo; 0.1% (1/1308) of Otezla patients discontinued treatment due to depression compared with none on placebo (0/506). Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide

— Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur

◆ Weight Decrease: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla

compared to 1% (3/382) of patients treated with placebo. Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla

◆ Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions ◆ Adverse reactions reported in ≥5% of patients were (Otezla%,

placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)

Use in Specific Populations◆ Pregnancy and Nursing Mothers: Otezla is Pregnancy

Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when Otezla is administered to a nursing woman

◆ Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information

Please turn the page for Brief Summary of Full Prescribing Information.

References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation; 2014. 2. Data on file, Celgene Corporation.

Get the latest news at otezlapro.com

Single page A-size ad • Trim: 8.5” x 10.875” • Bleed: 8.5” x 11.25” • Live: 7.5” x 9.75”

Otezla® is a registered trademark of Celgene Corporation.© 2015 Celgene Corporation 03/15 USII-APR150063

C M Y KCosmos Communications 1

1ej

30306a 03.25.15 133

Q1 Q2

OTEZLA® (apremilast) tablets, for oral useThe following is a Brief Summary; refer to Full Prescribing Information forcomplete product information.INDICATIONS AND USAGEOTEZLA® (apremilast) is indicated for the treatment of patients with moderateto severe plaque psoriasis who are candidates for phototherapy or systemictherapy.CONTRAINDICATIONSOTEZLA is contraindicated in patients with a known hypersensitivity toapremilast or to any of the excipients in the formulation [see Adverse Reactions(6.1)].WARNINGS AND PRECAUTIONSDepression: Treatment with OTEZLA is associated with an increase in adversereactions of depression. Before using OTEZLA in patients with a history ofdepression and/or suicidal thoughts or behavior prescribers should carefullyweigh the risks and benefits of treatment with OTEZLA in such patients.Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or othermood changes, and if such changes occur to contact their healthcare provider.Prescribers should carefully evaluate the risks and benefits of continuingtreatment with OTEZLA if such events occur. During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.3% (12/920) of patientstreated with OTEZLA reported depression compared to 0.4% (2/506) treatedwith placebo. During the clinical trials, 0.1% (1/1308) of patients treated withOTEZLA discontinued treatment due to depression compared with none inplacebo-treated patients (0/506). Depression was reported as serious in 0.1%(1/1308) of patients exposed to OTEZLA, compared to none in placebo-treatedpatients (0/506). Instances of suicidal behavior have been observed in 0.1%(1/1308) of patients while receiving OTEZLA, compared to 0.2% (1/506) inplacebo-treated patients. In the clinical trials, one patient treated with OTEZLAattempted suicide while one who received placebo committed suicide. Weight Decrease: During the controlled period of the trials in psoriasis, weightdecrease between 5%-10% of body weight occurred in 12% (96/784) of patientstreated with OTEZLA compared to 5% (19/382) treated with placebo. Weightdecrease of ≥10% of body weight occurred in 2% (16/784) of patients treatedwith OTEZLA 30 mg twice daily compared to 1% (3/382) patients treated withplacebo. Patients treated with OTEZLA should have their weight monitoredregularly. If unexplained or clinically significant weight loss occurs, weight lossshould be evaluated, and discontinuation of OTEZLA should be considered. Drug Interactions: Co-administration of strong cytochrome P450 enzymeinducer, rifampin, resulted in a reduction of systemic exposure of apremilast,which may result in a loss of efficacy of OTEZLA. Therefore, the use ofcytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital,carbamazepine, phenytoin) with OTEZLA is not recommended [see DrugInteractions (7.1) and Clinical Pharmacology (12.3)]. ADVERSE REACTIONSClinical Trials Experience in Psoriasis: Because clinical trials are conductedunder widely varying conditions, adverse reaction rates observed in the clinicaltrial of a drug cannot be directly compared to rates in the clinical trials ofanother drug and may not reflect the rates observed in clinical practice. Diarrhea,nausea, and upper respiratory tract infection were the most commonly reported adverse reactions. The most common adverse reactions leading todiscontinuation for patients taking OTEZLA were nausea (1.6%), diarrhea(1.0%), and headache (0.8%). The proportion of patients with psoriasis whodiscontinued treatment due to any adverse reaction was 6.1% for patientstreated with OTEZLA 30 mg twice daily and 4.1% for placebo-treated patients.Table 3: Adverse Reactions Reported in ≥1% of Patients on OTEZLA and WithGreater Frequency Than in Patients on Placebo; up to Day 112 (Week 16)

Placebo OTEZLA 30 mg BIDPreferred Term (N=506) (N=920)

n (%) n (%)Diarrhea 32 (6) 160 (17)Nausea 35 (7) 155 (17)Upper respiratory tract infection 31 (6) 84 (9)Tension headache 21 (4) 75 (8)Headache 19 (4) 55 (6)Abdominal pain* 11 (2) 39 (4)Vomiting 8 (2) 35 (4)Fatigue 9 (2) 29 (3)

(continued)

Table 3: Adverse Reactions Reported in ≥1% of Patients on OTEZLA and WithGreater Frequency Than in Patients on Placebo; up to Day 112 (Week 16)

Placebo OTEZLA 30 mg BIDPreferred Term (N=506) (N=920)

n (%) n (%)Dyspepsia 6 (1) 29 (3)Decrease appetite 5 (1) 26 (3)Insomnia 4 (1) 21 (2)Back pain 4 (1) 20 (2)Migraine 5 (1) 19 (2)Frequent bowel movements 1 (0) 17 (2)Depression 2 (0) 12 (1)Bronchitis 2 (0) 12 (1)Tooth abscess 0 (0) 10 (1)Folliculitis 0 (0) 9 (1)Sinus headache 0 (0) 9 (1)

*Two subjects treated with OTEZLA experienced serious adverse reaction ofabdominal pain.Severe worsening of psoriasis (rebound) occurred in 0.3% (4/1184) patientsfollowing discontinuation of treatment with OTEZLA (apremilast).DRUG INTERACTIONSStrong CYP 450 Inducers: Apremilast exposure is decreased when OTEZLA isco-administered with strong CYP450 inducers (such as rifampin) and mayresult in loss of efficacy [see Warnings and Precautions (5.3) and ClinicalPharmacology (12.3)].USE IN SPECIFIC POPULATIONSPregnancy: Pregnancy Category C: OTEZLA should be used during pregnancyonly if the potential benefit justifies the potential risk to the fetus. PregnancyExposure Registry: There is a pregnancy exposure registry that monitorspregnancy outcomes in women exposed to OTEZLA during pregnancy.Information about the registry can be obtained by calling 1-877-311-8972.Nursing Mothers: It is not known whether OTEZLA or its metabolites are presentin human milk. Because many drugs are present in human milk, caution shouldbe exercised when OTEZLA is administered to a nursing woman. Pediatric use:The safety and effectiveness of OTEZLA in pediatric patients less than 18 yearsof age have not been established. Geriatric use: Of the 1257 patients whoenrolled in two placebo-controlled psoriasis trials (PSOR 1 and PSOR 2), a totalof 108 psoriasis patients were 65 years of age and older, including 9 patientswho were 75 years of age and older. No overall differences were observed in the efficacy and safety in elderly patients ≥65 years of age and younger adultpatients <65 years of age in the clinical trials. Renal Impairment: OTEZLApharmacokinetics were not characterized in patients with mild (creatinineclearance of 60-89 mL per minute estimated by the Cockcroft–Gault equation) or moderate (creatinine clearance of 30-59 mL per minute estimated by theCockroft–Gault equation) renal impairment. The dose of OTEZLA should bereduced to 30 mg once daily in patients with severe renal impairment (creatinineclearance of less than 30 mL per minute estimated by the Cockroft–Gaultequation) [see Dosage and Administration (2.2) and Clinical Pharmacology(12.3)]. Hepatic Impairment: Apremilast pharmacokinetics were characterizedin patients with moderate (Child Pugh B) and severe (Child Pugh C) hepaticimpairment. No dose adjustment is necessary in these patients.OVERDOSAGEIn case of overdose, patients should seek immediate medical help. Patientsshould be managed by symptomatic and supportive care should there be anoverdose.Manufactured for: Celgene Corporation, Summit, NJ 07901

OTEZLA® is a registered trademark of Celgene Corporation.

Pat. http://www.celgene.com/therapies©2014 Celgene Corporation, All Rights Reserved.

Based on APRPI.003 OTZ_PsO_HCP_BSv.003 09_2014

Rx Only

Single page A-size ad • Trim: 8.5” x 10.875” • Bleed: 8.5” x 11.25” • Live: 7.5” x 9.75”

KCosmos Communications 1

1ej

30306a 03.25.15 133

Q1 Q2

Anita completed her first of many triathlons at age 57.

Pfizer developed Get Old to challenge us to rethinkaging and take a more active role in our health.

At Pfizer, we make medicines and vaccines that extend and improve lives, yet we know that medicines alone cannot give you a healthy life.

It’s time to challenge how we think about aging and look forward to what’s yet to come.To learn more, visit GetOld.com.

©2013 The GlaxoSmithKline Group of Companies All rights reserved. Printed in USA. January 2013

We Offer More Than Face Time.If you haven’t heard, GSK is moving forward by aligning our actions with managed care executives’ expectations. This means we are continuously investing in the strategic expertise of our account managers to understand your needs.

Diffi cult challenges, such as improving population outcomes, abound for managed care organizations—and that’s where the account managers at GSK can bring together experts who offer credible scientifi c and economic knowledge that can provide insights to inform your solutions.

True collaboration is more than face time—it’s moving forward with solutions that meet your needs.

MANAGED MARKETS

An eye care company that puts your plan’s needs in view.

Visionary.

At Alcon, we know that you need a partner who understands your organization and its members. Our expertise in both vision care and managed markets allows us to deliver exactly what you need—leading pharmaceuticals and vision care products.

Contact your Account Manager today. Together we can make sure youand your members see things clearly.

©2015 Novartis 2/15 MGC15003JAD

90619_MGC15003JAD.indd 1 8/6/15 12:07 PM

Your partner in Biopharmaceuticals.Pioneers in

Dedicated to helping you provide affordable, high-quality

Biopharmaceuticals

© 2014 Sandoz Inc. All Rights Reserved. OMNI0574 10/2014

Call your Account Manager for more information, or reach us at http://sandoz.com/tools/contact_us/

and we will have your Account Manager contact you

FOCUSED ON LIFE.

MEDIVATION.

DRIVEN BY SCIENCE.

© 2015 Medivation, Inc. All rights reserved. Printed in USA. PRM-MDV-US-0010 8/15

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families.

Visit medivation.com to learn more about our commitment to patients with serious diseases.

MEDIVATION IS PROUD TO SUPPORT THE PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

S:7”

S:10”T:8.5”

T:11”B:8.75”

B:11.25”

www.vrtx.com

© 2014 Vertex Pharmaceuticals Incorporated 9/14

THE SCIENCE of POSSIBILITY

Vertex creates new possibilities in medicine to cure diseases and improve people’s lives. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.

Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN 55369 | 1-800-654-2299© 2015 Upsher-Smith Laboratories, Inc. 108177.01

We are a US-based company founded by a pharmacist, so we never forget the essential role that pharmacists play in the health and well-being of the community. The care you provide is recognized and respected. Supporting you is what drives us to be the best at every level of our business, and to meet our customers’ needs, including providing a continuous supply of reliable, affordable, quality products.

We believe that, as pharmacists, you help patients get the best benefits from their medications. Our perspective is not more products, but the right products to make people’s lives better. This aligns with our mission to improve people’s lives through innovative pharmacotherapy.

Together, we can make a difference—improving people’s lives.

Visit upsher-smith.com to learn more.

ROOTED IN A LONG AND PROUD TRADITIONOF SUPPORTINGPHARMACISTS

www.acorda.com

Acorda’s mission is to develop therapies that restore function and improve the lives of people with neurological disorders. We are proud to be a sponsor of the Pharmaceutical Care Management Association’s Annual Meeting.

The stylized Acorda logo is a trademark of Acorda Therapeutics, Inc.© 2015 Acorda Therapeutics, Inc. All rights reserved. 8/15 MS3735

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

DSNA15102072 06/15

Eisai’s passionate commitment to patient care

is the driving force behind our efforts to fi nd

innovative solutions that help address unmet

medical needs and contribute to the well-

being of patients worldwide. With therapies

in oncology and specialty care, we focus on

having an impact on patients and their families.

At Eisai, human health care is our goal.

Passionate about patient care

CORP0400 ©2015 Eisai Inc. All rights reserved. July 2015 www.eisai.com/us

CORP0400 Corporate Ad PCMA 2015.indd 1 7/1/15 11:02 AM

Johnson & Johnson Health Care Systems Inc. (JJHCS), a Johnson & Johnson company, provides contracting, supply chain and business services to key health care customers, including hospital systems and group purchasing organizations, leading health plans, and government health care institutions, in the United States. This ability to partner with many different customer groups makes JJHCS essential to the success of the Johnson & Johnson Family of Companies.

Through its Customer Service Centers, JJHCS touches customers of the Johnson & Johnson Family of Companies more than 9,500 times per day. The company manages countless electronic orders for products via its “e” channels. JJHCS executes contracted sales—1.2 million orders—for several U.S. medical device companies. JJHCS also processes customer rebates and chargebacks on behalf of U.S.-based Johnson & Johnson Medical Devices & Diagnostics, Pharmaceutical and Consumer companies.

www.ucb.com

Connecting with patients“ I would like to change the perception of rheumatoid arthritis and increase public awareness. It is associated with the elderly, but it is a disease that can happen to anyone at any age. I’m grateful for the therapies that are available now to help sufferers live their lives as best they can.”

Alison, living with rheumatoid arthritis

UCB has a passionate, long-term commitment to help patients and families living with severe diseases lead normal, everyday lives.

Our ambition is to offer them innovative new medicines and ground-breaking solutions in two main therapeutic areas: neurology and immunology. We foster cutting-edge scientific research that is guided by patients’ needs.

www.ucb.com

SHICO2462_PCMA_Sponsorship_Ad_FINAL.indd

ClientJob

LiveTrim

Bleed

UsersCurrent Date

Creation Date

Printed atPage #

ShireSHICO 2462

None7.5” x 4.75”None

Christian’s Capsule / Derek Rush 8-27-2015 12:18 PM7-10-2015 9:59 AM

None1

Job Info Approvals

FontsHelvetica Neue (65 Medium, 55 Roman)

Inks Cyan, Magenta, Yellow, Black Images

ShiCo_Bansi-Riya_Gaucher_disease_4C.tif (CMYK; 945 ppi; 31.73%), Shire_Logo_PMS3005_4C.eps (25.42%)

Art DirectorCopywriterAccountStudio ArtistProofreaderProject Mgr

Steve Brittany x273christian x212 Meredith x239

MATERIALS PREPARED BY SEIDEN

212.223.8700

FinalRound:

Notes

shire.com

We enable people with life-altering conditions to lead better lives.

As a leader in the development and marketing of orphan drugs, Shire brings hope to those with rare conditions.

T:7.5”

T:4.75”

Lundbeck is a pharmaceutical company committed to improving the lives of those suffering from psychiatric and neurological disorders.

We support and participate in hundreds of community awareness and educational events each year. This participation fuels our passion to make a difference, one patient at a time.

To learn more about Lundbeck, visit www.lundbeckus.com.

UBR-D-00077

People creating new products for better health worldwide

The name “Otsuka” translates to “major milestone.”

And indeed, for over 85 years, Otsuka’s people have achieved major milestones in their quest to create new products for better health. Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal, and central nervous systems, and to treat cancer and ophthalmic disorders. We’ve funded new research, supported new clinical trials, and pursued the development of new medications – an unfaltering commitment of energy and resources with one goal in mind – to create new products for better health worldwide.

1.800.562.3974 www.otsuka-us.comOtsuka America Pharmaceutical, Inc.Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka Maryland Medicinal Laboratories, Inc.

© 2014 Otsuka America Pharmaceutical, Inc. February 2014 01US14EUP0002

SEEING COMPLEXITY IN A NEW LIGHT.For 150 years, Mallinckrodt has made complex scientific problems manageable, developing valuable diagnostic tools and treatments for patients who need them.

We view challenges as opportunities. See how at Mallinckrodt.com

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2015 Mallinckrodt. May 2015

For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.

MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.BUT THEY BEGIN IN THE HEART.

For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400. Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0006 01/13

MerckAd_Lab_Half_Clr.indd 1 2/5/13 10:24 AM

75 YEARS OF IMPROVINGTHE HEALTH & WELL-BEINGOF PEOPLE WORLDWIDEAt Grifols, we are proud of our pioneering spirit and history of innovation. In 1940, we founded a company that has helped transform hematology. Today, we are a global leader providing live-saving protein therapies, diagnostic solutions, and other tools that hospitals, pharmacies, and healthcare professionals need to deliver expert medical care.

PCMA_grifols_AD.indd 1 23/7/15 16:23

At Bristol-Myers Squibb, our commitment to develop innovative medicines is as strong as the patient’s will to fi ght serious diseases.

We are working every day to develop the next generation of treatments in areas such as:

• Cardiovascular • Fibrotic Diseases• Genetically De� ned Diseases• Immuno-Oncology• Immunoscience• Oncology• Virology

At Bristol-Myers Squibb, our commitment

Fighting Serious Diseases

© 2015 Bristol-Myers Squibb Company. All rights reserved.

To learn more about our commitment to patients around the world, visit www.bms.com

There are 7 billion reasons why we do what we do.

At Mylan, we are committed to

setting new standards in

healthcare. Working together around

the world to provide 7 billion people

access to high quality medicine, we: • Innovate to satisfy unmet needs • Make reliability and service

excellence a habit • Do what’s right, not what’s easy • Impact the future through

passionate global leadership

Mylan.com

A privately held pharmaceutical company founded by physicians, Purdue is dedicated to meeting the needs of our Managed Care partners by developing programs that improve both patient care and patient safety:

• PartnersAgainstPain.com offers people living with pain, as well as their friends and families, comprehensive and clear information on a wide variety of pain issues

• RxSafetyMatters.org is an online resource for healthcare professionals, law enforcement, and community organizations to help combat the illegal diversion and abuse of prescription medications

A positive impact.On healthcare. And on lives.

Decisions that fit Programs that matter Solutions that count

©2012 Purdue Pharma L.P., Stamford, CT 06901-3431 B8248-HP 3/12

PurduePharma.com

Proud sponsors of

W W W.VALEA NT.COM

Valeant Pharmaceuticals International, Inc. is

committed to innovation and to introducing

products that make a meaningful difference

in patient’s lives.

Please contact Jenny Dawson to learn more about the Affiliate Program, sponsorship opportunities, registration, housing and other general conference inquiries.

Jenny Dawson Senior Manager, Conferences and Development

jdawson@pcmanet .org 202 .756 .5721

ANNUAL MEETING 2016

September 19 & 20 THE WESTIN KIERLAND SCOTTSDALE, AZ

BUSINESSFORUM 2016A DIVISION OF THE

Pharmaceutical Care Management Association

February 8 & 9 JW MARRIOTT ORLANDO GRANDE LAKES ORLANDO, FL

SAVE-THE-DATE

Pharmaceutical Care Management Association325 7th Street, nW, 9th floor

Washington, DC 20004

www .pcmanet .org

WE HAVE MOVED . PLEASE NOTE OUR NEW ADDRESS .

annual meeting 2015 · welcome to the 2015 pcma annual meeting the pcma annual meeting is the...

Documents